drugset / Trial / NCT05097378

Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

NCT05097378

RandomizedParallel-groupOpen-labelTreatment

Summary

A two-arm, randomised trial investigating the response of encorafenib and binimetinib compared to standard adjuvant therapy.

Timeline

Start
2022-01-01
Primary completion
2023-09-01
Completion
2024-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Binimetinib Small molecule 45 mg Oral
Subject Encorafenib Small molecule 450 mg Oral

Indications